Japan Will Grapple With Mixed Reimbursement Policy In The Year Ahead
This article was originally published in PharmAsia News
A Supreme court decision and TPP negotiations all point to further discussion around kongo shinryo – or mixed reimbursement – for treatments.
You may also be interested in...
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.